Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
113.09
-1.64 (-1.43%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
73
74
Next >
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
September 18, 2023
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 14, 2023
Via
Benzinga
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm
September 13, 2023
Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony.
Via
InvestorPlace
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention
September 13, 2023
By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology...
Via
Benzinga
Why Is Moderna Stock Trading Higher Today?
September 13, 2023
Moderna Inc (NASDAQ: MRNA) announced its intentions to launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials over the next five years.
Via
Benzinga
Why MERCK & CO. INC. (NYSE:MRK) should be investigated by quality investors.
August 28, 2023
Why MERCK & CO. INC. (NYSE:MRK) should be investigated by quality investors.
Via
Chartmill
Looking At Merck & Co's Recent Unusual Options Activity
August 23, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Merck & Co
August 22, 2023
Via
Benzinga
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
September 13, 2023
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite.
Via
Investor's Business Daily
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
September 11, 2023
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.
Via
Benzinga
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
September 07, 2023
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.
Via
InvestorPlace
The 25 Best Stocks By Shareholder Wealth Creation (1926-2022)
September 06, 2023
Via
Talk Markets
Healthcare Portfolio: A Mixed Market Looking for Value
September 05, 2023
Many healthcare stocks may be defensive in nature but if you are overweight the basic plays like the XLV or biotech funds like the Fidelity Biotechnology Fund you are trailing the market over the past...
Via
Talk Markets
3 Forever Stocks to Buy With $100
September 05, 2023
With $100 or less, you can buy at least one share of one of these top stocks.
Via
The Motley Fool
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
September 05, 2023
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'...
Via
Benzinga
Exposures
COVID-19
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
September 05, 2023
On Friday, Judge Thomas Rose, serving in the U.S.
Via
Benzinga
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
September 02, 2023
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?
Via
The Motley Fool
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
August 29, 2023
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations.
Via
The Motley Fool
Cannabis Industry's Capital Crunch: Why It Needs More Funds Than Other Industries, Will Fed Legalization Change This?
August 29, 2023
Recent research conducted by Viridian Capital Advisors reveals that the cannabis sector requires more capital as compared to other similar industries.
Via
Benzinga
Topics
Cannabis
Economy
Exposures
Cannabis
Interest Rates
Steady Eddies: 7 Unshakeable Stocks for Any Type of Market
August 29, 2023
With economic circumstances treading in uncertain waters, investors may want the confidence of safe stocks to buy.
Via
InvestorPlace
Better Pharma Growth Stock: Eli Lilly vs. Merck
August 29, 2023
This is a close contest, but there's a clear winner.
Via
The Motley Fool
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
August 29, 2023
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including:
Via
Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
August 29, 2023
The Biden administration is planning to negotiate the prices of 10 drugs in 2026.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
August 28, 2023
Via
Benzinga
Viridian Chart Of The Week: How Capital Intensive Is Cannabis?
August 28, 2023
The chart explores the capital intensity of cannabis compared to four other industries thought to be likely suitors for cannabis companies upon federal legalization: Tobacco, Alcoholic Beverages,...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications
August 28, 2023
Some of the most frequently prescribed medications in the U.S. might soon become more affordable.
Via
Benzinga
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
August 25, 2023
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S.
Via
Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
August 25, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck...
Via
Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
August 23, 2023
Roche provided an update from its study in lung cancer using an anti-TIGIT drug.
Via
Investor's Business Daily
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
73
74
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.